RecruitingNCT02253251
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
Sponsor
MiraKind
Enrollment
15,000 participants
Start Date
Sep 1, 2014
Study Type
OBSERVATIONAL
Conditions
Summary
The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies. The investigators will allow individuals to obtain their results through a physician at the completion of the studies. The investigators current focus is cancer and autoimmunity.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Personal or family history of cancer
- Personal history of endometriosis, or autoimmunity
Exclusion Criteria2
- Younger than 18
- Non-english speaking and unable to understand and sign the consent
Interventions
GENETICKRAS-variant and microRNA binding site mutation testing
Participant in these studies will be tested for the KRAS-variant
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02253251
Related Trials
Small Bowel Capsule Endoscopy in Lynch Syndrome
NCT074726861 location
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
NCT068355699 locations
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
NCT043337063 locations
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT0653305951 locations
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
NCT070727283 locations